Malinowska B, Piszcz J, Schlicker E, Kramer K, Elz S, Schunack W
Zakład Fizjologii Doświadczalnej, Akademia Medyczna, Białystok, Poland.
Naunyn Schmiedebergs Arch Pharmacol. 1999 Jan;359(1):11-6. doi: 10.1007/pl00005316.
Selective H2- and H3-receptor agonists, exhibiting an at least tenfold higher potency than histamine itself at the respective receptors, have been known for several years. Selective H1-receptor agonists with a potency exceeding that of histamine have become available only recently; the most potent are methylhistaprodifen and dimethylhistaprodifen [Nalpha-methyl- and Nalpha,Nalpha-dimethyl-2(3,3-diphenylpropyl)histamine, respectively] with 3.4- and 2.4-fold higher potencies than histamine in vitro (in the guinea-pig ileum). The aim of the present study was to examine whether these compounds and the parent compound histaprodifen are potent H1-receptor agonists in the pithed and in the anaesthetized rat. In pithed, vagotomized rats diastolic blood pressure was decreased by 2-(2-thiazolyl)ethanamine i.v. (which was used as a reference H1-receptor agonist) and by histaprodifen, methylhistaprodifen, and dimethylhistaprodifen; the maximum decrease was about 45 mmHg for each compound, and the potencies, expressed as pED50, the negative logarithm of the dose (in mole per kilogram body weight) eliciting a half-maximal response, were 7.23, 7.55, 8.43 and 8.12, respectively. The dose/response curves of the four compounds were shifted to the right to about the same extent by the H1-receptor antagonist dimetindene (1 micromol/kg i.v.). The vasodepressor response was not affected by combined i.v. administration of the H2- and H3-receptor antagonists ranitidine and thioperamide, by combined i.v. administration of the alpha1- and alpha2-adrenoceptor antagonists prazosin and rauwolscine, and by the beta-adrenoceptor antagonist propranolol i.v. but was attenuated by the inhibitor of NO synthase, N(omega)-nitro-L-arginine methyl ester i.v. In anaesthetized rats 2-(2-thiazolyl)ethanamine, histaprodifen, methylhistaprodifen and dimethylhistaprodifen i.v. also decreased diastolic blood pressure in a manner sensitive to dimetindene i.v. Our data show that histaprodifen and, in particular, methyl and dimethylhistaprodifen are highly potent H1-receptor agonists in vivo.
选择性H2和H3受体激动剂在各自受体上的效力比组胺本身至少高10倍,这类激动剂已被人们知晓数年。效力超过组胺的选择性H1受体激动剂直到最近才出现;其中效力最强的是甲基组胺丙二苯醚和二甲基组胺丙二苯醚[分别为Nα-甲基-和Nα,Nα-二甲基-2(3,3-二苯基丙基)组胺],在体外(豚鼠回肠)其效力分别比组胺高3.4倍和2.4倍。本研究的目的是检验这些化合物以及母体化合物组胺丙二苯醚在脊髓切断和麻醉大鼠体内是否为强效H1受体激动剂。在脊髓切断、迷走神经切断的大鼠中,静脉注射2-(2-噻唑基)乙胺(用作参考H1受体激动剂)以及组胺丙二苯醚、甲基组胺丙二苯醚和二甲基组胺丙二苯醚均可使舒张压降低;每种化合物的最大降幅约为45 mmHg,以pED50(引起半数最大反应的剂量的负对数,单位为摩尔每千克体重)表示的效力分别为7.23、7.55、8.43和8.12。H1受体拮抗剂二甲茚定(静脉注射1 μmol/kg)使这四种化合物的剂量/反应曲线向右移动的程度大致相同。静脉联合注射H2和H3受体拮抗剂雷尼替丁和硫代哌酰胺、静脉联合注射α1和α2肾上腺素能受体拮抗剂哌唑嗪和萝芙木碱以及静脉注射β肾上腺素能受体拮抗剂普萘洛尔均不影响血管减压反应,但静脉注射一氧化氮合酶抑制剂N(ω)-硝基-L-精氨酸甲酯可减弱该反应。在麻醉大鼠中,静脉注射2-(2-噻唑基)乙胺、组胺丙二苯醚、甲基组胺丙二苯醚和二甲基组胺丙二苯醚也会使舒张压降低,且对静脉注射二甲茚定敏感。我们的数据表明,组胺丙二苯醚,尤其是甲基和二甲基组胺丙二苯醚在体内是强效H1受体激动剂。